NASDAQ · Health Information Services · USD
GoodRx Holdings, Inc. (GDRX) Stock Analysis
GoodRx Holdings, Inc. (GDRX) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
GDRX Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.51
- Previous Close
- $3.52
- Day's Range
- 3.46–3.63
- 52-Week Range
- 1.77–4.05
- Volume
- 1.76M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.69
Valuation
- Market Cap
- $1.22B
- P/E Ratio
- 71.40
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 10.14
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 1.55
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.05
Financials (FY)
- Revenue (FY)
- $796.85M+0.57%
- Net Income (FY)
- $30.44M+85.72%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 2.07%
- Shares Outstanding
- 107.18M
- 1-Year Return
- −8.23%
Dividend and dates
- Earnings Date
- November 3, 2026
- Avg Volume
- 1.28M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, GDRX closed at $3.57, −8.23% over 1 year.
GoodRx Holdings, Inc. (GDRX) has a market capitalization of $1.22B.
In fiscal 2025, GDRX reported revenue of $796.85M.
GDRX Stock Return by Calendar Year
GoodRx Holdings, Inc. (GDRX) return since Sep 2020: what $10,000 became
- 1 year
- $10,000 $9,177
- −8.23%
- 5 years
- $10,000 $760
- −92.40%
- Since Sep 2020
- $10,000 $707
- −92.93%
If you had invested $10,000 in GoodRx Holdings, Inc. (GDRX) at the close on September 23, 2020, the earliest close on record here, it would have been worth $707 at the close on October 21, 2026: −92.93% in total, −35.34% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +31.73% |
| 2025 | −41.72% |
| 2024 | −30.60% |
| 2023 | +43.78% |
| 2022 | −85.74% |
| 2021 | −18.99% |
| 2020 (partial year) | −20.12% |
As of October 21, 2026.
GDRX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $796.85M | $30.44M | 3.8% |
| 2024 | $792.32M | $16.39M | 2.1% |
| 2023 | $750.27M | −$8.87M | −1.2% |
| 2022 | $766.55M | −$32.83M | −4.3% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $796.85M | $739.26M | $87.49M | $30.44M | 3.8% |
| 2024 | $792.32M | $744.11M | $65.85M | $16.39M | 2.1% |
| 2023 | $750.27M | $683.34M | −$27.01M | −$8.87M | −1.2% |
| 2022 | $766.55M | $701.48M | $1.74M | −$32.83M | −4.3% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
GDRX Valuation vs Health Information Services Median
Median of 44 stocks| Metric | GDRX | Health Information Services median | vs median |
|---|---|---|---|
| P/E | 71.40 | 46.54 | 53% above |
| P/S ratio | 1.55 | 2.31 | 33% below |
| Profit margin | 2.07% | −7.55% | 9.6 pts above |
Medians across 44 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
GoodRx Holdings And 2 Penny Stocks With Strong Balance Sheets
Yahoo3 Reasons to Avoid GDRX and 1 Stock to Buy Instead
YahooFull Transcript: GoodRx Holdings Q2 2026 Earnings Call
BenzingaAmazon (AMZN) and GoodRx (GDRX) Chase Prescription Subscribers as Insurance Coverage Slips
YahooFrom Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household
YahooBarclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4
Benzinga
All 14 articles ↓Show fewer ↑
UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75
BenzingaGoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope
SeekingAlphaCitigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5
BenzingaTD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5
BenzingaGoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
SeekingAlphaGoodRx (NASDAQ:GDRX) Q2 2026: Subscription and Pharma Direct Growth Lift Shares Despite Revenue Decline
ChartMillGoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M Est
BenzingaGoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Health Information Services Stocks
Veeva Systems Inc.
$51.90B
BTSGBrightSpring Health Services, Inc.
$12.40B
TEMTempus AI, Inc.
$12.23B
HNGEHinge Health, Inc.
$9.04B
HQYHealthEquity, Inc.
$8.10B
DOCSDoximity, Inc.
$5.99B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B










